+

WO2009132928A3 - Marqueurs moléculaires pour le pronostic d'un cancer - Google Patents

Marqueurs moléculaires pour le pronostic d'un cancer Download PDF

Info

Publication number
WO2009132928A3
WO2009132928A3 PCT/EP2009/054034 EP2009054034W WO2009132928A3 WO 2009132928 A3 WO2009132928 A3 WO 2009132928A3 EP 2009054034 W EP2009054034 W EP 2009054034W WO 2009132928 A3 WO2009132928 A3 WO 2009132928A3
Authority
WO
WIPO (PCT)
Prior art keywords
high risk
risk
low risk
outcome
gene expression
Prior art date
Application number
PCT/EP2009/054034
Other languages
English (en)
Other versions
WO2009132928A2 (fr
Inventor
Udo Stropp
Christian VON TÖRNE
Mathias Gehrmann
Ralf Kronenwett
Original Assignee
Siemens Healthcare Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics Gmbh filed Critical Siemens Healthcare Diagnostics Gmbh
Publication of WO2009132928A2 publication Critical patent/WO2009132928A2/fr
Publication of WO2009132928A3 publication Critical patent/WO2009132928A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur un procédé d'identification d'un ensemble de gènes donnant des informations sur l'issue d'une maladie qui peuvent être combinées en un algorithme pour un test pronostique ou prédictif. L'algorithme fait usage de données d'expression génique provenant d'échantillons biologiques et définit si les patients ont un risque élevé ou un risque faible, par exemple chez des patients cancéreux, un groupe à issue favorable ou à issue défavorable de métastase. Des profils de référence d'expression génique sont obtenus pour les groupes à risque élevé et à faible risque, respectivement. Un échantillon d'un patient inconnu est analysé et classé comme appartenant au groupe à risque élevé ou à risque faible, respectivement, en fonction de la corrélation avec le profil de référence de risque élevé ou au profil de référence de risque faible.
PCT/EP2009/054034 2008-05-02 2009-04-03 Marqueurs moléculaires pour le pronostic d'un cancer WO2009132928A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08008371 2008-05-02
EP08008371.0 2008-05-02

Publications (2)

Publication Number Publication Date
WO2009132928A2 WO2009132928A2 (fr) 2009-11-05
WO2009132928A3 true WO2009132928A3 (fr) 2009-12-23

Family

ID=40875041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/054034 WO2009132928A2 (fr) 2008-05-02 2009-04-03 Marqueurs moléculaires pour le pronostic d'un cancer

Country Status (1)

Country Link
WO (1) WO2009132928A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063274A2 (fr) * 2009-11-23 2011-05-26 Genomic Health, Inc. Procédés destinés à prédire l'issue clinique d'un cancer
FI20105252A0 (fi) 2010-03-12 2010-03-12 Medisapiens Oy Menetelmä, järjestely ja tietokoneohjelmatuote biologisen tai lääketieteellisen näytteen analysoimiseen
EP2845911B1 (fr) 2010-03-31 2016-05-18 Sividon Diagnostics GmbH Procédé de prédiction de la récurrence du cancer du sein sous traitement endocrinien
EP2844776B1 (fr) 2012-04-30 2019-06-12 The Research Foundation for The State University of New York Test sanguin de dépistage du cancer utilisant de l'arn bc200 isolé à partir de sang périphérique et utilisable en vue du diagnostic et du traitement du cancer du sein invasif
WO2014118333A1 (fr) 2013-02-01 2014-08-07 Sividon Diagnostics Gmbh Procédé permettant de prédire le bénéfice d'inclure un taxane dans un régime chimiothérapeutique destiné à des patients atteints d'un cancer du sein
EP3679160A4 (fr) 2017-09-08 2021-05-19 Myriad Genetics, Inc. Procédé d'utilisation de biomarqueurs et de variables cliniques pour prédire l'intérêt d'une chimiothérapie

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158399A1 (en) * 1995-03-03 2003-08-21 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
WO2005033699A2 (fr) * 2003-10-03 2005-04-14 Ncc Technology Ventures Pte Limited Dispositifs et methodes destines a la classification du cancer du sein
WO2006136314A1 (fr) * 2005-06-23 2006-12-28 Siemens Medical Solutions Diagnostics Gmbh Particules magnetiques comportant une couche de silice fermee ultrafine, leur procede de production, et leur utilisation
WO2007030611A2 (fr) * 2005-09-09 2007-03-15 The Board Of Regents Of The University Of Texas System Indice calcule d'expression genomique de recepteurs des oestrogenes (er) et genes associes aux er

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158399A1 (en) * 1995-03-03 2003-08-21 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
WO2005033699A2 (fr) * 2003-10-03 2005-04-14 Ncc Technology Ventures Pte Limited Dispositifs et methodes destines a la classification du cancer du sein
WO2006136314A1 (fr) * 2005-06-23 2006-12-28 Siemens Medical Solutions Diagnostics Gmbh Particules magnetiques comportant une couche de silice fermee ultrafine, leur procede de production, et leur utilisation
WO2007030611A2 (fr) * 2005-09-09 2007-03-15 The Board Of Regents Of The University Of Texas System Indice calcule d'expression genomique de recepteurs des oestrogenes (er) et genes associes aux er

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GLINSKY G V ET AL: "Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 10, no. 7, 1 April 2004 (2004-04-01), pages 2272 - 2283, XP002309961, ISSN: 1078-0432 *
SORLIE T ET AL: "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 19, 11 September 2001 (2001-09-11), pages 10869 - 10874, XP002215483, ISSN: 0027-8424 *
VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO2009132928A2 (fr) 2009-11-05

Similar Documents

Publication Publication Date Title
KR20220015367A (ko) 메틸화된 핵산의 고심도 시퀀싱 방법 및 시스템
Brentani et al. Gene expression arrays in cancer research: methods and applications
Dyrskjøt et al. Identifying distinct classes of bladder carcinoma using microarrays
US9057108B2 (en) Hybrid model for the classification of carcinoma subtypes
Tsoucas et al. Recent progress in single-cell cancer genomics
Fan et al. Methods for genome-wide DNA methylation analysis in human cancer
NZ593226A (en) Gene expression markers (efnb2) for colorectal cancer prognosis
WO2009132928A3 (fr) Marqueurs moléculaires pour le pronostic d'un cancer
Gnanapragasam Unlocking the molecular archive: the emerging use of formalin‐fixed paraffin‐embedded tissue for biomarker research in urological cancer
WO2007136724A3 (fr) Procédé d'analyse automatique des tissus
WO2007050777A3 (fr) Procedes et compositions servant a diagnostiquer le cancer des poumons au moyen de profils specifiques de methylation d'adn
CN110706749A (zh) 一种基于组织器官分化层次关系的癌症类型预测系统和方法
US20110224908A1 (en) Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
Chung et al. Gene expression profiling of papillary thyroid carcinomas in Korean patients by oligonucleotide microarrays
CN106868204A (zh) 一种用于胃腺癌诊断的生物标志物
CN102782151A (zh) 作为用于前列腺癌诊断和分期的非侵入性标志物的循环miRNA
Teufel et al. Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration
WO2006038089A3 (fr) Procede pour identifier une transformation neoplasique avec une reference particuliere au cancer de la prostate
Osunkoya et al. Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis
WO2008104984A3 (fr) Diagnostic et pronostic de divers types de cancers
CN111100863B (zh) 小rna组成的指纹图谱在肺癌的诊断和治疗中的应用
WO2010046530A8 (fr) Procédés et utilisations mettant en oeuvre des aberrations génétiques de nav3 et l'expression aberrante de gènes multiples
US20170183738A1 (en) Process, Apparatus or System and Kit for Classification of Tumor Samples of Unknown and/or Uncertain Origin and Use of Genes of the Group of Biomarkers
CN107109397B (zh) 小型rna的表达量的修正方法和装置
EP2906713A1 (fr) Biomarqueurs de microarn pour le cancer de la prostate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09737972

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09737972

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载